Analytical Data
-
Gene name
Cystatin-8/CST8
- Application
-
Alternative Names
Cystatin-related epididymal spermatogenic protein; Cystatin-8; CRES
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60676
-
Expression Region
K22-A142
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
43-55 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cystatin-8 (CST8) is a member of the cystatin superfamily, which comprises a group of proteins known for their role as cysteine protease inhibitors. It is predominantly expressed in various tissues, including the brain and immune cells, and plays crucial roles in regulating inflammation, immune responses, and tissue remodeling. Dysregulation of CST8 has been associated with several pathological conditions, including cancer and neurodegenerative diseases. Due to its protective role in inhibiting proteases that can lead to tissue damage, CST8 has garnered attention for its potential therapeutic applications. Research has shown that recombinant CST8 protein can be produced through recombinant DNA technology, allowing for large-scale studies of its biological functions and interactions. Investigating CST8 at the molecular level can provide insights into its mechanistic pathways and its involvement in disease processes. Furthermore, the development of CST8 as a biomarker for disease prognosis or a target for drug development is an active area of research. As scientists aim to unravel its multifaceted roles, studies on recombinant CST8 are pivotal for understanding its biological significance and for exploring novel therapeutic strategies that could exploit its protective functions in various diseases.
